| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0891988710383573 |
| P698 | PubMed publication ID | 20923757 |
| P50 | author | Blair R Leavitt | Q84165482 |
| P2093 | author name string | Aaron Sturrock | |
| P2860 | cites work | CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup | Q24644358 |
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation | Q28246858 | ||
| Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death | Q28287762 | ||
| Selective sparing of a class of striatal neurons in Huntington's disease | Q45297134 | ||
| Sleep disturbances and severity of Huntington's disease | Q45297195 | ||
| Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease | Q45298031 | ||
| Huntington disease in a nonagenarian mistakenly diagnosed as normal pressure hydrocephalus | Q45298171 | ||
| Regional cortical thinning in preclinical Huntington disease and its relationship to cognition | Q45298420 | ||
| A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. | Q45298582 | ||
| Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. | Q45299923 | ||
| Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles | Q45300045 | ||
| Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial | Q45300094 | ||
| Decreased expression of striatal signaling genes in a mouse model of Huntington's disease | Q45300376 | ||
| Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin | Q45301569 | ||
| At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled | Q45301820 | ||
| Speech and language delay are early manifestations of juvenile-onset Huntington disease | Q45302788 | ||
| Effect of donepezil on motor and cognitive function in Huntington disease | Q45302793 | ||
| Two years' follow-up of rivastigmine treatment in Huntington disease. | Q45304063 | ||
| Testicular degeneration in Huntington disease. | Q45304856 | ||
| Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study | Q45305040 | ||
| Huntington's disease like-2 neuropathology | Q45305202 | ||
| Regional and progressive thinning of the cortical ribbon in Huntington's disease | Q45305508 | ||
| Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopy | Q45305917 | ||
| Riluzole in Huntington's disease: a 3-year, randomized controlled study | Q45305925 | ||
| 1H magnetic resonance spectroscopy in preclinical Huntington disease | Q45305972 | ||
| A South African mixed ancestry family with Huntington disease-like 2: clinical and genetic features | Q45305978 | ||
| Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. | Q45307199 | ||
| Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis | Q45307235 | ||
| Reduced expression of preproenkephalin in striatal neurons from huntington's disease patients | Q45307627 | ||
| Do defecs in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? | Q48317832 | ||
| Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. | Q48373564 | ||
| Huntington disease | Q48465200 | ||
| Neuropeptide Y, somatostatin, and reduced nicotinamide adenine dinucleotide phosphate diaphorase in the human striatum: a combined immunocytochemical and enzyme histochemical study. | Q50904251 | ||
| Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro | Q28584697 | ||
| Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice | Q29615357 | ||
| A randomized, placebo-controlled trial of latrepirdine in Huntington disease | Q30411257 | ||
| Comorbidities of obsessive and compulsive symptoms in Huntington's disease | Q30430896 | ||
| Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. | Q30445013 | ||
| Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study | Q30445842 | ||
| Clinical correlation of striatal 1H MRS changes in Huntington's disease | Q30581695 | ||
| Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease | Q30979352 | ||
| Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. | Q31129663 | ||
| Memory disorders associated with Huntington's disease: verbal recall, verbal recognition and procedural memory | Q33365782 | ||
| Magnetic resonance imaging of Huntington's disease: preparing for clinical trials | Q33437923 | ||
| Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data | Q33489152 | ||
| Five year study of prenatal testing for Huntington's disease: demand, attitudes, and psychological assessment | Q33595540 | ||
| Increased rate of suicide among patients with Huntington's disease | Q33620527 | ||
| Late onset of Huntington's disease | Q33621109 | ||
| Differential loss of striatal projection neurons in Huntington disease | Q33637273 | ||
| Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease | Q33703899 | ||
| Are there multiple pathways in the pathogenesis of Huntington's disease? | Q33703905 | ||
| Striatal and white matter predictors of estimated diagnosis for Huntington disease | Q33941486 | ||
| Transcriptional dysregulation in Huntington's disease | Q34001953 | ||
| Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo | Q34044164 | ||
| Juvenile onset Huntington's disease--clinical and research perspectives. | Q34091006 | ||
| Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice | Q34098463 | ||
| Loss of normal huntingtin function: new developments in Huntington's disease research | Q34142361 | ||
| Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid | Q34384772 | ||
| Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. | Q34565156 | ||
| CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches | Q34624785 | ||
| The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test | Q34680311 | ||
| Huntington's disease phenocopy syndromes | Q34712082 | ||
| A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease | Q34795840 | ||
| Huntington's chorea. Report of 3 cases and review of the literature | Q35115751 | ||
| Alternative excitotoxic hypotheses | Q35227246 | ||
| Neuropsychiatric aspects of Huntington's disease. | Q35463916 | ||
| Integrating fetal neural transplants into a therapeutic strategy: the example of Huntington's disease | Q35718776 | ||
| Longitudinal change in basal ganglia volume in patients with Huntington's disease | Q45293834 | ||
| New tools for preimplantation genetic diagnosis of Huntington's disease and their clinical applications | Q45295014 | ||
| Orexin loss in Huntington's disease. | Q45295272 | ||
| Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. | Q45295709 | ||
| 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers | Q45296001 | ||
| Critical periods of suicide risk in Huntington's disease | Q45296374 | ||
| The causes of sporadic and 'senile' chorea | Q45296612 | ||
| Huntington's disease and other choreas. | Q45296799 | ||
| Huntington disease: clinical, genetic, and social aspects | Q45297052 | ||
| Mitochondria take center stage in aging and neurodegeneration | Q36264218 | ||
| Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study | Q36900936 | ||
| Detection of Huntington's disease decades before diagnosis: the Predict-HD study | Q36941187 | ||
| Huntington's disease: progress and potential in the field | Q37016096 | ||
| Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset | Q37073913 | ||
| Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity | Q37132239 | ||
| Mutation in Huntington's chorea | Q37134786 | ||
| DNA sequence variation in a 3.7-kb noncoding sequence 5' of the CYP1A2 gene: implications for human population history and natural selection | Q37218857 | ||
| Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey | Q37222254 | ||
| Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease | Q37311202 | ||
| Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea | Q39109797 | ||
| Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids | Q39114293 | ||
| Huntington disease: finding the gene and after | Q39489967 | ||
| An outline for the analysis of dementia: The memory disorder of Huntingtons disease | Q39835513 | ||
| Aging, energy, and oxidative stress in neurodegenerative diseases. | Q40478731 | ||
| Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release | Q40551652 | ||
| Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. | Q40721588 | ||
| Preimplantation diagnosis for Huntington's disease (HD): clinical application and analysis of the HD expansion in affected embryos. | Q40974688 | ||
| Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk | Q41123560 | ||
| Characteristics of individuals with Huntington disease in long-term care | Q41159922 | ||
| Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract | Q41182414 | ||
| A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon | Q41197259 | ||
| Estimation of fertility and fitness in Huntington disease in New England | Q41232581 | ||
| Clinical Aspects of CAG Repeat Diseases | Q41527046 | ||
| Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases | Q42454434 | ||
| Early onset Huntington disease: a neuronal degeneration syndrome | Q42466838 | ||
| Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease | Q42503175 | ||
| Decreased frontal choline and neuropsychological performance in preclinical Huntington disease | Q42509872 | ||
| Predictive testing for Huntington's disease | Q42882096 | ||
| Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals | Q43411918 | ||
| Factors associated with slow progression in Huntington's disease | Q43593771 | ||
| NMDA receptor function in mouse models of Huntington disease | Q43825271 | ||
| Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. | Q43854094 | ||
| Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease | Q43925468 | ||
| Presymptomatic, prenatal, and exclusion testing for Huntington disease using seven closely linked DNA markers | Q44228164 | ||
| Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease | Q44480462 | ||
| The quinolinic acid model of Huntington's disease: locomotor abnormalities | Q45021251 | ||
| Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease | Q45100272 | ||
| Creatine supplementation lowers brain glutamate levels in Huntington's disease | Q45239341 | ||
| Psychopathology in Huntington's disease patients | Q45288763 | ||
| Huntington disease-like 2: the first patient with apparent European ancestry. | Q45288979 | ||
| Hereditary late-onset chorea without significant dementia: genetic evidence for substantial phenotypic variation in Huntington's disease | Q45288982 | ||
| Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease | Q45289366 | ||
| Highly disabling cerebellar presentation in Huntington disease. | Q45289403 | ||
| Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization | Q45291026 | ||
| Immune markers for Huntington's disease? | Q45292011 | ||
| Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk | Q45292147 | ||
| A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. | Q45292888 | ||
| Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease | Q45292937 | ||
| Basal ganglia volume and proximity to onset in presymptomatic Huntington disease | Q45293561 | ||
| P433 | issue | 4 | |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 243-259 | |
| P577 | publication date | 2010-10-05 | |
| P1433 | published in | Journal of Geriatric Psychiatry and Neurology | Q6295256 |
| P1476 | title | The clinical and genetic features of Huntington disease | |
| P478 | volume | 23 |
| Q89493910 | Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease |
| Q45292387 | Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease |
| Q35227496 | Changes in BiP availability reveal hypersensitivity to acute endoplasmic reticulum stress in cells expressing mutant huntingtin |
| Q35738853 | Characterising Upper Limb Movements in Huntington's Disease and the Impact of Restricted Visual Cues. |
| Q44832011 | Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors |
| Q37250319 | Development of the HD-Teen Inventory |
| Q36303727 | Development of the Huntington disease work function scale |
| Q34135360 | Effect of enhanced voluntary physical exercise on brain levels of monoamines in Huntington disease mice |
| Q27346849 | Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease |
| Q39015525 | Ethical aspects of a predictive test for Huntington's Disease: A long term perspective |
| Q45289680 | Ethical aspects of undergoing a predictive genetic testing for Huntington's disease |
| Q89619689 | Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington's Disease Patients |
| Q38629175 | Evolving Motivations: Patients' and Caregivers' Perceptions About Seeking Myotonic Dystrophy (DM1) and Huntington's Disease Care |
| Q34095823 | Examination of Huntington's disease in a Chinese family |
| Q36459384 | Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse |
| Q45303139 | Huntingtin interacting proteins 14 and 14-like are required for chorioallantoic fusion during early placental development. |
| Q37186056 | Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes |
| Q38663090 | Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets. |
| Q30578636 | Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin. |
| Q35126285 | Identification of binding sites in Huntingtin for the Huntingtin Interacting Proteins HIP14 and HIP14L |
| Q45294608 | Impact of Huntington Disease Gene-Positive Status on Pre-Symptomatic Young Adults and Recommendations for Genetic Counselors |
| Q36183886 | Is There an Association of Physical Activity with Brain Volume, Behavior, and Day-to-day Functioning? A Cross Sectional Design in Prodromal and Early Huntington Disease |
| Q26752867 | Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding |
| Q45297368 | Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease |
| Q38236849 | Palmitoylation and depalmitoylation defects |
| Q26747019 | Palmitoylation in Alzheimer's disease and other neurodegenerative diseases |
| Q45294016 | Participants at the Leiden Site of the REGISTRY Study: A Demographic Approach |
| Q28661435 | Plants and phytochemicals for Huntington's disease |
| Q27011417 | Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease |
| Q33556293 | Presentation and care of a family with Huntington disease in a resource-limited community |
| Q37284637 | Progression of motor subtypes in Huntington's disease: a 6-year follow-up study. |
| Q35660733 | Progressive Impairment of Lactate-based Gluconeogenesis in the Huntington's Disease Mouse Model R6/2 |
| Q33693989 | Pulmonary function in patients with Huntington's disease |
| Q45303456 | Respiratory muscle training on pulmonary and swallowing function in patients with Huntington's disease: a pilot randomised controlled trial |
| Q90682346 | Spectrum of tau pathologies in Huntington's disease |
| Q37138372 | Strategies used by teens growing up in families with Huntington disease |
| Q34994813 | Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis |
| Q64913350 | Swallowing impairment in neurologic disorders: the role of videofluorographic swallowing study. |
| Q90287496 | The First Case of Spinocerebellar Ataxia Type 8 in Monozygotic Twins |
| Q89744068 | The Ripple Effect: A Qualitative Overview of Challenges When Growing Up in Families Affected by Huntington's Disease |
| Q37862785 | Therapeutic applications of antibodies in non-infectious neurodegenerative diseases |
| Q38109547 | Two decades of Huntington disease testing: patient's demographics and reproductive choices |
| Q37943395 | What monozygotic twins discordant for phenotype illustrate about mechanisms influencing genetic forms of neurodegeneration |
Search more.